Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.verified

ACRS

Price:

$1.11

Market Cap:

$79.10M

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moder...[Read more]

Industry

Medical - Diagnostics & Research

IPO Date

2015-10-06

Stock Exchange

NASDAQ

Ticker

ACRS

The PE Ratio as of May 2024 (TTM) for Aclaris Therapeutics, Inc. (ACRS) is -1.02

According to Aclaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.02. This represents a change of -83.10% compared to the average of -6.03 of the last 4 quarters.

Aclaris Therapeutics, Inc. (ACRS) Historical PE Ratio (quarterly & annually)

How has ACRS PE Ratio performed in the past?

The mean historical PE Ratio of Aclaris Therapeutics, Inc. over the last ten years is -7.14. The current -1.02 PE Ratio has changed 1.33% with respect to the historical average. Over the past ten years (40 quarters), ACRS's PE Ratio was at its highest in in the September 2001 quarter at 0. The PE Ratio was at its lowest in in the December 2015 quarter at -25.48.

Quarterly (TTM)
Annual

Average

-7.14

Median

-7.61

Minimum

-13.76

Maximum

-0.55

Aclaris Therapeutics, Inc. (ACRS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Aclaris Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 884.08%

Maximum Annual PE Ratio = -0.55

Minimum Annual Increase = -92.85%

Minimum Annual PE Ratio = -13.76

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.83-92.85%
2022-11.5860.50%
2021-7.2234.15%
2020-5.38884.08%
2019-0.55-70.16%
2018-1.83-81.88%
2017-10.11-16.34%
2016-12.0951.09%
2015-8.00-41.86%
2014-13.76-38.52%

Aclaris Therapeutics, Inc. (ACRS) Average PE Ratio

How has ACRS PE Ratio performed in the past?

The current PE Ratio of Aclaris Therapeutics, Inc. (ACRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-6.54

5-year avg

-5.11

10-year avg

-7.14

Aclaris Therapeutics, Inc. (ACRS) PE Ratio vs. Peers

How is ACRS’s PE Ratio compared to its peers?

Aclaris Therapeutics, Inc.’s PE Ratio is less than Neogen Corporation (1.83K), less than Qiagen N.V. (28.79), greater than Olink Holding AB (publ) (-88.46), less than Syneos Health, Inc. (62.97), less than Sotera Health Company (57.56), less than RadNet, Inc. (190.75), greater than Myriad Genetics, Inc. (-6.90), less than Genetron Holdings Limited (-0.63), greater than Biodesix, Inc. (-2.99), greater than Castle Biosciences, Inc. (-21.75), greater than Prenetics Global Limited (-1.07), less than IQVIA Holdings Inc. (30.78), less than Medpace Holdings, Inc. (38.55), less than ICON Public Limited Company (38.77),

Build a custom stock screener for Aclaris Therapeutics, Inc. (ACRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aclaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aclaris Therapeutics, Inc. (ACRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aclaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Aclaris Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Aclaris Therapeutics, Inc. (ACRS)?

What is the highest PE Ratio for Aclaris Therapeutics, Inc. (ACRS)?

What is the 3-year average PE Ratio for Aclaris Therapeutics, Inc. (ACRS)?

What is the 5-year average PE Ratio for Aclaris Therapeutics, Inc. (ACRS)?

How does the current PE Ratio for Aclaris Therapeutics, Inc. (ACRS) compare to its historical average?